In advanced NSCLC, high IL-1β levels were identified as an adverse prognostic factor associated with shorter progression-free and OS [24], while in head and neck cancer elevated IL-1α correlated with an increased risk of distant metastasis [25]. The gene discussed is IL1A; the disease is non-small cell lung carcinoma.